UBS Group Reiterates Sell Rating for AstraZeneca (LON:AZN)
UBS Group reiterated their sell rating on shares of AstraZeneca (LON:AZN) in a report issued on Monday, Borsen Zeitung reports. UBS Group currently has a GBX 5,800 ($76.30) price target on the biopharmaceutical company’s stock.
Other analysts have also recently issued reports about the company. Morgan Stanley raised their price target on AstraZeneca from GBX 7,400 ($97.34) to GBX 8,100 ($106.55) and gave the company an equal weight rating in a research note on Monday, January 6th. Liberum Capital reiterated a buy rating on shares of AstraZeneca in a research report on Friday, February 14th. JPMorgan Chase & Co. set a GBX 8,500 ($111.81) target price on AstraZeneca and gave the stock a buy rating in a research report on Friday, February 14th. Citigroup reiterated a buy rating on shares of AstraZeneca in a research report on Tuesday, January 28th. Finally, Goldman Sachs Group set a GBX 6,000 ($78.93) target price on AstraZeneca and gave the stock a sell rating in a research report on Friday, February 14th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company. AstraZeneca currently has a consensus rating of Buy and an average target price of GBX 7,890.71 ($103.80).
AstraZeneca stock opened at GBX 7,604 ($100.03) on Monday. AstraZeneca has a 1-year low of GBX 109.51 ($1.44) and a 1-year high of GBX 8,227.88 ($108.23). The company has a debt-to-equity ratio of 148.59, a current ratio of 0.92 and a quick ratio of 0.70. The stock has a market cap of $99.39 billion and a PE ratio of 47.70. The stock’s fifty day moving average is GBX 7,630.50 and its two-hundred day moving average is GBX 7,357.78.
In other news, insider Michel Demare bought 700 shares of the business’s stock in a transaction dated Monday, February 17th. The shares were acquired at an average price of GBX 7,313 ($96.20) per share, for a total transaction of £51,191 ($67,338.86).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: What does the Producer Price Index (PPI) tell investors?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.